Lumos Diagnostics Holdings (ASX:LDX) progressed numerous additional pilot sites with new urgent care operators/chains for its FebriDx rapid point-of-care test for acute respiratory infections, according to a Monday Australian bourse filing.

The eight urgent care chains run by new operator ownership groups are progressing favourably in their evaluation and implementation of FebriDx, it added.

Lumos is also receiving regular reimbursement updates through its consultants, PRO-spectus and AcuityMD, and is beginning to see early data from sites using FebriDx, which suggests that over 90% of submitted claims are being reimbursed.

Its shares rose 4% in recent trading on Monday.